
Pavan Kumar Prathipati

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3574987/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeted Immuno-Antiretroviral to Promote Dual Protection against HIV: A Proof-of-Concept Study. Nanomaterials, 2022, 12, 1942.	1.9	Ο
2	A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	7
3	Formulation and characterization of ternary amorphous solid dispersions of a highly potent anti-tubercular agent and curcumin. Journal of Drug Delivery Science and Technology, 2021, 64, 102564.	1.4	6
4	Surface plasmon resonance, Orbitrap mass spectrometry and Raman advancements: exciting new techniques in drug discovery. Expert Opinion on Drug Discovery, 2020, 15, 739-743.	2.5	4
5	A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study. Antiviral Research, 2019, 167, 83-88.	1.9	33
6	A review of CCR5 antibodies against HIV: current and future aspects. Therapeutic Delivery, 2019, 10, 107-112.	1.2	5
7	2501. CCR5 Targeted ARV Loaded Nanoparticle: Dual Protection for HIV Functional Cure. Open Forum Infectious Diseases, 2019, 6, S867-S868.	0.4	Ο
8	Development and validation of LC–MS/MS method for quantification of bictegravir in human plasma and its application to an intracellular uptake study. Biomedical Chromatography, 2019, 33, e4379.	0.8	15
9	Indole-2-Carboxamides Are Active against <i>Mycobacterium abscessus</i> in a Mouse Model of Acute Infection. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	28
10	Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission. Journal of Controlled Release, 2019, 294, 216-225.	4.8	37
11	Discovery of a non-nucleoside RNA polymerase inhibitor for blocking Zika virus replication through in silico screening. Antiviral Research, 2018, 151, 78-86.	1.9	53
12	LC–MS/MS method for the simultaneous determination of tenofovir, emtricitabine, elvitegravir and rilpivirine in dried blood spots. Biomedical Chromatography, 2018, 32, e4270.	0.8	6
13	Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics. Current HIV Research, 2018, 15, 411-421.	0.2	40
14	Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study. Antiviral Research, 2018, 156, 85-91.	1.9	36
15	Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model. Pharmaceutical Research, 2017, 34, 2749-2755.	1.7	32
16	Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission. Aids, 2017, 31, 469-476.	1.0	45
17	Cellulose Acetate Phthalate and Antiretroviral Nanoparticle Fabrications for HIV Pre-Exposure Prophylaxis. Polymers, 2017, 9, 423.	2.0	17
18	Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC–MS/MS and its application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2016, 129, 473-481.	1.4	28